Stylus Medicine
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Stylus Medicine firmographics
Firmographics- Name
- Stylus Medicine
- Legal name
- Stylus Medicine, Inc.
- Website
- https://stylusmedicine.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Stylus Medicine industry classification
Industry- Product category
- Genetic Medicines
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- Lead Optimization & Preclinical Candidate Selection (HLAIALAB), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where Stylus Medicine is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Stylus Medicine business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biopharmaceutical Development and Commercialization: Pre-revenue biotech company developing genetic medicines. Revenue will be generated through commercialization of CAR-T therapies and other genetic medicines upon successful clinical development and regulatory approval. Currently in preclinical stage with testing in non-human primates.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Stylus Medicine product offering
Product offeringCore offering
Stylus Medicine develops a proprietary in vivo genetic medicines platform that pairs engineered therapeutic-grade large serine recombinases (LSR) with cell-targeted lipid nanoparticle (LNP) delivery to enable precise, durable integration of therapeutic payloads directly inside the body. Its lead application is in vivo CAR-T cell therapy for oncology, which is designed to program immune cells in vivo without ex vivo cell manufacturing, with planned expansion into autoimmune and genetic disease indications.
Product overview
Stylus Medicine is a biotechnology company developing a unified in vivo genetic medicines platform centered on engineered large serine recombinases (LSR) combined with cell-targeted lipid nanoparticle (LNP) delivery. The company's flagship offering is its in vivo CAR-T therapy platform, which enables precise, durable CAR-T generation inside the body. The platform features three integrated components: a therapeutic-grade recombinase capable of encoding polyfunctional multi-kb payloads, a customizable genetic payload, and a targeted LNP delivery system. Initial therapeutic focus is on oncology applications with plans to expand to autoimmune and genetic diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- In Vivo Genetic Medicines Platform A platform that combines engineered therapeutic-grade large serine recombinases (LSR) with cell-targeted lipid nanoparticle (LNP) delivery to enable precise, durable, and scalable in vivo cell engineering via sequence-specific genome integration at safe harbor sites without exposed double-stranded breaks.
- In Vivo CAR-T Therapies Off-the-shelf in vivo CAR-T cell therapies that use the company's recombinase and LNP platform to genetically program T cells inside the patient's body, delivering therapeutic payloads directly to immune cells and eliminating the need for ex vivo cell manufacturing. Initial focus is oncology (including hematological malignancies), with planned expansion to autoimmune and genetic diseases.
Quantifiable outcome
- Single dose of in vivo CAR-T therapy demonstrated rapid and sustained tumor regression in humanized NSG mouse tumor model
Companies that use Stylus Medicine
Customer profileSegments3 records
Ideal customer profiles2 records
Stylus Medicine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
Stylus Medicine partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Stylus Medicine competitors and assessment
Company assessmentDirect peers
- Tessera Therapeutics: Tessera is developing in vivo gene writing using engineered recombinases combined with LNP delivery — architecturally the closest analog to Stylus Medicine. Both companies pursue sequence-specific genome integration to enable durable cell reprogramming inside the body, competing for similar talent, investors, and pharma partnerships.
- Prime Medicine: Prime Medicine is advancing in vivo prime editing, a next-generation gene-editing modality aimed at precise genomic corrections without double-stranded breaks. It competes with Stylus for the same in vivo genetic-medicine opportunity and partnership mindshare among large pharmas.
- Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR/Cas9 company developing both in vivo gene editing and ex vivo cell therapies including CAR-T. It is one of the most advanced competitors in in vivo gene editing and shares Stylus's focus on durable genomic modifications.
- Beam Therapeutics: Beam is developing in vivo base editing for hematologic and other genetic diseases and is also expanding into CAR-T. It competes with Stylus for in vivo cell-engineering programs and shares a focus on precise, single-base-level genome modification in patients.
- Verve Therapeutics: Verve is an in vivo gene-editing company using base editing and LNP delivery for cardiovascular disease. It is comparable to Stylus in its use of LNP-based in vivo delivery to permanently modify human cells, though Verve targets different tissues and indications.
- Editas Medicine: Editas is developing in vivo and ex vivo CRISPR-based gene-editing therapies, including cell-therapy programs. It overlaps directly with Stylus's ambition to create durable, in vivo genome modifications for serious diseases.
Broad incumbents
- Sangamo Therapeutics: Sangamo is a clinical-stage gene-editing and cell-therapy company using zinc finger nucleases and other modalities. CSO Jason Fontenot's prior employer and a broad incumbent in genomic medicine, representing established competition and a potential acquirer.
- BlueRock Therapeutics: BlueRock is a clinical-stage cell-therapy company focused on engineered cell therapies, including iPSC-derived therapies for neurological and cardiovascular indications. It is comparable as a broader cell-therapy incumbent, and was previously led by Stylus CEO Emile Nuwaysir before Bayer's acquisition.
Emerging players
- Ensoma: Ensoma is developing in vivo gene therapy using engineered viral vectors and genomic medicines for hematopoietic cells. It is directly comparable to Stylus in targeting immune-cell modification in vivo, and was previously led by CEO Emile Nuwaysir.
- Generation Bio: Generation Bio is a non-viral genetic-medicines company developing LNP-delivered gene therapies for rare diseases. It shares Stylus's non-viral, LNP-based in vivo delivery approach and is pursuing permanent genomic integration for durable therapeutic effect.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Stylus Medicine social profiles
Digital presenceStylus Medicine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Stylus Medicine leadership team
Management profileNumber of profiles
Profiles6 records
Stylus Medicine funding detail
Funding detailFunding overview
Funding rounds1 record
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Stylus Medicine M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Stylus Medicine
What does Stylus Medicine do?
Stylus Medicine develops a proprietary in vivo genetic medicines platform that pairs engineered therapeutic-grade large serine recombinases (LSR) with cell-targeted lipid nanoparticle (LNP) delivery to enable precise, durable integration of therapeutic payloads directly inside the body. Its lead application is in vivo CAR-T cell therapy for oncology, which is designed to program immune cells in vivo without ex vivo cell manufacturing, with planned expansion into autoimmune and genetic disease indications.
Is Stylus Medicine a public or private company?
Stylus Medicine is a private company. It is classified as venture growth investor backed and is currently operating.
When was Stylus Medicine founded?
Stylus Medicine was founded in 2022. It employs 11 to 50 people.
Where is Stylus Medicine based?
Stylus Medicine is headquartered in Cambridge, United States, in the North America region.
How does Stylus Medicine make money?
One revenue line is on record: biopharmaceutical Development and Commercialization.
Who are Stylus Medicine's main competitors?
Direct peers on record are Tessera Therapeutics, Prime Medicine, Intellia Therapeutics, Beam Therapeutics, Verve Therapeutics and Editas Medicine. Broad incumbents are Sangamo Therapeutics and BlueRock Therapeutics. Emerging players are Ensoma and Generation Bio.
Does Stylus Medicine have an API?
No public API is recorded for Stylus Medicine.
What industry is Stylus Medicine in?
Stylus Medicine's product category is Genetic Medicines. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAIALAB, Lead Optimization & Preclinical Candidate Selection. Its NAICS code is 541714 and its SIC code is 2836.